DGS Capital Management LLC Takes Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

DGS Capital Management LLC bought a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBTFree Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 25,571 shares of the company’s stock, valued at approximately $156,000.

A number of other institutional investors and hedge funds have also modified their holdings of CLBT. Swiss National Bank boosted its stake in Cellebrite DI by 7.6% during the first quarter. Swiss National Bank now owns 89,000 shares of the company’s stock worth $570,000 after buying an additional 6,300 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Cellebrite DI by 159.3% during the first quarter. JPMorgan Chase & Co. now owns 49,499 shares of the company’s stock worth $317,000 after acquiring an additional 30,410 shares in the last quarter. Blair William & Co. IL lifted its holdings in shares of Cellebrite DI by 3,021.1% during the first quarter. Blair William & Co. IL now owns 523,978 shares of the company’s stock valued at $3,353,000 after acquiring an additional 507,190 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Cellebrite DI in the 1st quarter valued at $127,000. Finally, State Street Corp grew its holdings in shares of Cellebrite DI by 20.3% in the 1st quarter. State Street Corp now owns 155,440 shares of the company’s stock worth $995,000 after purchasing an additional 26,240 shares during the last quarter. 21.80% of the stock is currently owned by institutional investors.

Cellebrite DI Price Performance

Shares of Cellebrite DI stock opened at $7.28 on Thursday. The firm has a 50 day simple moving average of $7.55 and a 200 day simple moving average of $6.47. Cellebrite DI Ltd. has a fifty-two week low of $3.80 and a fifty-two week high of $8.29. The firm has a market cap of $1.42 billion, a P/E ratio of -34.67, a P/E/G ratio of 0.93 and a beta of 1.30.

Cellebrite DI (NASDAQ:CLBTGet Free Report) last released its earnings results on Tuesday, August 8th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.03 by $0.02. Cellebrite DI had a positive return on equity of 60.26% and a negative net margin of 13.89%. The company had revenue of $76.70 million during the quarter, compared to analysts’ expectations of $72.52 million. During the same period last year, the firm earned $0.00 EPS. The business’s revenue for the quarter was up 22.5% on a year-over-year basis. On average, sell-side analysts expect that Cellebrite DI Ltd. will post 0.19 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Craig Hallum began coverage on shares of Cellebrite DI in a research report on Wednesday, July 19th. They issued a “buy” rating and a $11.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and issued a $10.00 target price on shares of Cellebrite DI in a report on Wednesday, August 30th. TheStreet raised Cellebrite DI from a “d+” rating to a “c” rating in a report on Thursday, July 13th. JPMorgan Chase & Co. boosted their price objective on Cellebrite DI from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 9th. Finally, Bank of America increased their target price on Cellebrite DI from $6.15 to $6.75 in a report on Friday, June 16th.

Read Our Latest Research Report on CLBT

Cellebrite DI Company Profile

(Free Report)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the United States, and the Asia-Pacific. Its DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation.

Featured Stories

Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBTFree Report).

Institutional Ownership by Quarter for Cellebrite DI (NASDAQ:CLBT)

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.